(89)Zr-DFO-durvalumab PET/CT prior to durvalumab treatment in patients with recurrent or metastatic head and neck cancer. Verhoeff SR, van de Donk PP, Aarntzen EHJG, Oosting SF, et al. J Nucl Med 2022 May 5. pii: jnumed.121.263470. doi: 10.2967/jnumed.121.263470.

Read + Share

Amedeo Smart

Independent Medical Education

Verhoeff SR, van de Donk PP, Aarntzen EHJG, Oosting SF, et al. (89)Zr-DFO-durvalumab PET/CT prior to durvalumab treatment in patients with recurrent or metastatic head and neck cancer. J Nucl Med 2022 May 5. pii: jnumed.121.263470. doi: 10.2967/jnumed.121.263470.
PMID: 35512998